Head-to-head · free
Dianthus Therapeutics, Inc. vs DexCom, Inc.
DNTH vs DXCM — return on capital, cash generation, margins and balance sheet side by side.
DNTH
0 / 6
measures where DNTH leads
DXCM
6 / 6
measures where DXCM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | DNTH · FY2025 | DXCM · FY2025 |
|---|---|---|
| Revenue | $2.0M | $4.7B |
| Net income | (162.3M) | $836.3M |
| Revenue growth (yearly, multi-year) | -67.3% | 17.5% |
| Free cash flow | — | $1.1B |
| Free cash flow margin | — | 23.1% |
| Net cash / (debt) | — | — |
| ROIC | — | 15.8% |
| Return on equity | -38.4% | 34.5% |
| Gross margin | — | 60.1% |
| Operating margin | -8739.3% | 19.6% |
| Net debt / EBITDA | 0.29x | 0.28x |
Figures are as reported by each company; latest fiscal year shown.
Where Dianthus Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where DexCom, Inc.'s cash went (FY2025)
- Capital spending
- $363.5M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free